<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871467</url>
  </required_header>
  <id_info>
    <org_study_id>KW-5001-1</org_study_id>
    <nct_id>NCT01871467</nct_id>
  </id_info>
  <brief_title>Sargramostim for Myeloid Dendritic Cell Deficiency</brief_title>
  <official_title>Sargramostim for Myeloid Dendritic Cell Deficiency - Phase I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have demonstrated a deficiency of blood dendritic cells in patients with&#xD;
      kidney disease that is associated with the development of viral infections after kidney&#xD;
      transplantation. We plan to test the ability of sargramostim to increase blood dendritic cell&#xD;
      levels in patients with kidney disease in the hopes of developing new therapies to prevent&#xD;
      viral infections after kidney transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target blood myeloid dendritic cell level of &gt; 2.0 x 10&lt;4&gt;/mL</measure>
    <time_frame>2-4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Dendritic Cell Deficiency</condition>
  <arm_group>
    <arm_group_label>Sargramostim administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive sargramostim.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <arm_group_label>Sargramostim administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years &lt; 80 years with diagnosis of end stage renal disease and currently&#xD;
             undergoing outpatient hemodialysis (HD) at one of the Johns Hopkins&#xD;
             University-affiliated HD units&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18or&gt;80years&#xD;
&#xD;
          -  History of non-adherence to prescribed HD treatment&#xD;
&#xD;
          -  Active drug or heavy alcohol use (defined as &gt; 4 drinks/day)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Active infection (bacterial or viral) or clinically significant infections within the&#xD;
             past three months (e.g. those requiring hospitalization, or as judged by the PI)&#xD;
&#xD;
          -  Active malignancy (with the exception of excised non-metastatic basal cell carcinoma&#xD;
             or squamous cell carcinoma of the skin, or adequately treated pre- invasive cervical&#xD;
             cancer in situ)&#xD;
&#xD;
          -  Unstable cardiovascular status (angina, arrhythmias, congestive heart failure etc...)&#xD;
&#xD;
          -  History of liver disease (as defined by a diagnosis of uncompensated cirrhosis) â€¢&#xD;
             History of lung disease (including moderate-severe chronic obstructive pulmonary&#xD;
             disease, interstitial lung disease, or asthma)&#xD;
&#xD;
          -  Known hypersensitivity to yeast-derived products&#xD;
&#xD;
          -  Hemoglobin &lt; 10 g/dL and hematocrit &lt; 30%.&#xD;
&#xD;
          -  Abnormal white blood cell (WBC) count at baseline (&lt; 3 or &gt; 12 x 10 cells/mm )&#xD;
&#xD;
          -  Treatment with WBC growth factors (G-CSF or GM-CSF) or immunosuppressive medications&#xD;
             (tacrolimus, cyclosporine, mycophenolate, azathioprine, corticosteroids, chlorambucil,&#xD;
             cyclophosphamide) within 4 weeks of study (erythropoiesis-stimulating agents will be&#xD;
             allowed)&#xD;
&#xD;
          -  Treatment with lithium within 4 weeks of study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl L Womer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

